Status:
UNKNOWN
Enriched Eggs for Retina Health in Type 2 Diabetes
Lead Sponsor:
University of Manitoba
Collaborating Sponsors:
Egg Farmers of Canada
Conditions:
Diabetic Retinopathy
Type 2 Diabetes
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Diabetes mellitus has been declared a major public health issue. Among the complications of the disease, retinopathy can have a significant impact on mobility and quality of life for individuals livin...
Eligibility Criteria
Inclusion
- Adults (\>19 years of age)
- Individuals diagnosed with Type 2 diabetes
- Individuals taking oral hypoglycemic medications (sulfonylureas, meglitinides, biguanides, thiazolidinediones etc.)
- Individuals with a fasting plasma glucose of ≥7.0 mmol/L or glycated hemoglobin (A1C) of ≥6.5%. (these values are based on the Canadian Diabetes Association and are predictors of the development of diabetic retinopathy)
Exclusion
- Individuals previously diagnosed with moderate to severe diabetic retinopathy (to assess egg consumption as a preventative strategy for diabetic retinopathy).
- Individuals with eye disease (cataracts, glaucoma, age-related macular degeneration, retinitis pigmentosa, optic atrophy, and eye malformation etc.)
- Individuals with Alzheimer's, dementia or other mental cognitive diseases
- Individuals with Type 1 diabetes
- Individuals taking insulin
- Individuals diagnosed with cancer or anemia
- Pregnant women
Key Trial Info
Start Date :
July 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04496817
Start Date
July 11 2022
End Date
September 1 2024
Last Update
November 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asper Clinical Research Institute
Winnipeg, Manitoba, Canada, R2H 2A6